Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
出版年份 2021 全文链接
标题
Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
作者
关键词
-
出版物
Frontiers in Endocrinology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-10-22
DOI
10.3389/fendo.2021.738848
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease
- (2021) Dominique M. Bovée et al. HYPERTENSION
- A GLP-1 Receptor Agonist Inhibits Aldosterone Release in Healthy Volunteers
- (2021) Tuuli Sedman et al. HORMONE AND METABOLIC RESEARCH
- DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)–Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1–Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway
- (2020) Kosuke Okabe et al. HYPERTENSION
- Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System
- (2020) Mengying Yang et al. Frontiers in Pharmacology
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications
- (2020) Alejandrina M. Castañeda et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Sodium-glucose co-transporter-2 inhibitors: peculiar “hybrid” diuretics that protect from target organ damage and cardiovascular events
- (2020) Riccardo Sarzani et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Renal protection with glucagon-like peptide-1 receptor agonists
- (2020) Martina Vitale et al. CURRENT OPINION IN PHARMACOLOGY
- Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control
- (2020) Flavia L. Martins et al. HYPERTENSION
- The renal extraction and the natriuretic action of GLP-1 in humans depend on interaction with the GLP-1 receptor
- (2020) Ali Asmar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study
- (2020) Toshitaka Sawamura et al. BMC Endocrine Disorders
- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
- (2019) Theodosios D. Filippatos et al. POSTGRADUATE MEDICINE
- Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
- (2019) Tuba M. Ansary et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease
- (2019) Juliana Isa Beraldo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
- (2019) Milton Packer et al. EUROPEAN JOURNAL OF HEART FAILURE
- Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen
- (2019) Estrellita Uijl et al. HYPERTENSION
- A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion
- (2019) Satoru Kuriyama KIDNEY & BLOOD PRESSURE RESEARCH
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats
- (2019) Rong-Hua Zheng et al. Drug Design Development and Therapy
- Review of cardiovascular outcomes trials of sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists
- (2019) Emily J. North et al. CURRENT OPINION IN CARDIOLOGY
- Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial
- (2019) Ramón C Hermida et al. EUROPEAN HEART JOURNAL
- Conservation of glucagon like peptide-1 level with liraglutide and linagilptin protects the kidney against angiotensin II-induced tissue fibrosis in rats
- (2019) Feng Bai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
- (2018) Dorrin Zarrin Khat et al. Current Diabetes Reports
- Effects of SGLT2 Inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes
- (2018) ICHIRO MORI et al. DIABETES
- Economic Costs of Diabetes in the U.S. in 2017
- (2018) DIABETES CARE
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Angiotensinogen and Megalin Interactions Contribute to Atherosclerosis
- (2018) Feiming Ye et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide Enhances the Activity of the ACE-2/Ang(1–7)/Mas Receptor Pathway in Lungs of Male Pups from Food-Restricted Mothers and Prevents the Reduction of SP-A
- (2018) J. Fandiño et al. International Journal of Endocrinology
- Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study
- (2018) Maja Baretić et al. Diabetes Therapy
- Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation
- (2018) Jonathan P. Mochel et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes
- (2017) Takuo Yoshimoto et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
- (2016) J. Skov et al. DIABETES OBESITY & METABOLISM
- Liraglutide Treatment May Affect Renin and Aldosterone Release
- (2016) Tuuli Sedman et al. HORMONE AND METABOLIC RESEARCH
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
- (2016) Stella Bernardi et al. Journal of Diabetes Research
- Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
- (2016) Seok Joon Shin et al. PLoS One
- The Intrarenal Renin-Angiotensin System in Hypertension
- (2015) Robert M. Carey ADVANCES IN CHRONIC KIDNEY DISEASE
- Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men
- (2015) Ali Asmar et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart
- (2015) Li-Hui Zhang et al. CARDIOVASCULAR DRUGS AND THERAPY
- Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats
- (2015) Marina Romaní-Pérez et al. ENDOCRINOLOGY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review
- (2015) Varun Vaidya et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs
- (2014) Jonathan P. Mochel et al. CHRONOBIOLOGY INTERNATIONAL
- Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
- (2014) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
- (2014) Fan Jiang et al. Nature Reviews Cardiology
- Effects of GLP-1 in the Kidney
- (2014) Jeppe Skov REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- The Renin-Angiotensin-Aldosterone System and Heart Failure
- (2013) Gabriel Sayer et al. CARDIOLOGY CLINICS
- Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology
- (2013) Jonathan P. Mochel et al. CHRONOBIOLOGY INTERNATIONAL
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Oxidative Stress/Angiotensinogen/Renin-Angiotensin System Axis in Patients with Diabetic Nephropathy
- (2013) Masumi Kamiyama et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
- (2013) Jeppe Skov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
- (2013) Hiroki Fujita et al. KIDNEY INTERNATIONAL
- Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation
- (2013) Taiji Matsusaka et al. KIDNEY INTERNATIONAL
- New Frontiers in the Intrarenal Renin-Angiotensin System: A Critical Review of Classical and New Paradigms
- (2013) Jia L. Zhuo et al. Frontiers in Endocrinology
- Investigation of the haemodynamic effects of exenatide in healthy male subjects
- (2012) Buddhike Mendis et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Loss of Angiotensin-Converting Enzyme-2 Exacerbates Diabetic Cardiovascular Complications and Leads to Systolic and Vascular Dysfunction
- (2012) Vaibhav B. Patel et al. CIRCULATION RESEARCH
- Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKC Activation in Diabetes
- (2012) A. Mima et al. DIABETES
- Liver Angiotensinogen Is the Primary Source of Renal Angiotensin II
- (2012) T. Matsusaka et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A
- (2012) Yuji Ishibashi et al. MICROVASCULAR RESEARCH
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- It is Time to Reconsider the Cardiovascular Protection Afforded by RAAS Blockade - Overview of RAAS Systems
- (2011) Osamu Tsukamoto et al. CARDIOVASCULAR DRUGS AND THERAPY
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
- (2011) David R. Whiting et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The RAAS in the pathogenesis and treatment of diabetic nephropathy
- (2010) Piero Ruggenenti et al. Nature Reviews Nephrology
- Chronotherapy With the Angiotensin-Converting Enzyme Inhibitor Ramipril in Essential Hypertension
- (2009) Ramón C. Hermida et al. HYPERTENSION
- Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
- (2009) Jessie Gu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Angiotensin-(1–7) and the G Protein-Coupled Receptor Mas Are Key Players in Renal Inflammation
- (2009) Vanesa Esteban et al. PLoS One
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now